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Background: We have recently observed that skin reactivity to autologous serum injection
is common in patients with non-allergic asthma. However, clinical signiﬁcance of skin
reactivity to autologous serum remains to be deﬁned.
Objective: To evaluate the possible relation between skin reactivity to autologous serum
and clinical and laboratory characteristics in a series of patients with non-allergic asthma.
Methods: Fifty-ﬁve patients with non-allergic asthma underwent in vivo autologous serum
skin test (ASST) and in vitro basophil histamine release assay using basophils from a normal
donor. Clinical and laboratory characteristics including peripheral blood eosinophilia,
antinuclear antibodies and total IgE concentration were evaluated. As control, ASST was
performed in 10 allergic asthmatic patients, 10 patients with allergic rhinitis and 10
normal subjects.
Results: ASSTwas positive in 29/55 non-allergic asthmatics (53%), whereas it was negative
in all 30 control subjects (Po0.001). The sera of 6 out of 51 patients induced in vitro
histamine release from autologous basophils. The sera from two patients induced
histamine release from membrane IgE-stripped basophils. A signiﬁcant predominance of
female sex (83%) and a high incidence of antinuclear antibodies (ANA) positivity (55%) were
found among ASST-positive patients.
Conclusion: These ﬁndings indicate that ASST is positive in about half patients with non-
allergic asthma and that a proportion of patients (16%) has functional evidence of
circulating histamine-releasing factors. In addition, predominance of female sex and
frequent ANA positivity are in line with an autoimmune basis of non-allergic asthma.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
3632374; fax: +39 0263632243.
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An inﬂammatory process of respiratory airways underlies
both allergic and non-allergic asthma, but the triggering
event of bronchial inﬂammation has been identiﬁed only in
allergic asthma.1–3 In fact, allergen-induced mast cell
activation is the cause of inﬂammatory mediator release
and inﬂammatory cell recruitment in allergic asthma,
whereas the initial trigger in non-allergic asthma remains
obscure.4–9 Some epidemiological and experimental ﬁndings
suggest that allergic and non-allergic asthma are not clearly
distinct immunopathological entities.10 Burrows et al.11
showed a strong association between high levels of serum
total IgE and asthma either in allergic or non-allergic
asthmatics. This observation was conﬁrmed by Beeh
et al.,12 who found that elevation of total serum IgE is
associated with asthma in non-allergic individuals, support-
ing the role of IgE as risk factor for asthma independent of
allergy. Furthermore, a local IgE production has been
demonstrated in bronchial biopsies from non-allergic asth-
matics.13 On the other hand, some clinical and immuno-
pathological ﬁndings allow to distinguish allergic and non-
allergic asthma: for example, non-allergic asthma has a
later onset in life, female preponderance, a more frequent
association to nasal polyposis and a more severe clinical
course.1 Additionally, analysis of blood and bronchoalveolar
lavage cells as well as bronchial biopsies from allergic
asthmatics have revealed a predominant activation of TH2
lymphocytes with enhanced production of interleukin (IL)-4,
IL-5 and IL-13.6 Conversely, cytokine production in non-
allergic asthmatics is not so clearly TH2-oriented: in fact an
increased production of either IL-2, a TH1 cytokine, or IL-5,
a TH2 cytokine, has been detected in non-allergic asth-
matics.7
We have recently shown that intradermal injection of
autologous serum causes a wheal and ﬂare reaction in about
half the patients with non-allergic asthma.14 We hypothe-
sized that a circulating histamine-releasing factor, that has
not been characterized yet, could account for skin reactivity
to autologous serum. A WHEAL and ﬂare reaction following
intradermal injection of autologous serum was originally
described in chronic urticaria patients and was shown to be
associated with autoantibodies directed against the high
afﬁnity IgE receptor or against IgE, or with a mast-cell
speciﬁc histamine-releasing factor.15–18 Circulating hista-
mine-releasing factors might activate bronchial and pul-
monary mast cells, thus initiating or perpetuating bronchial
inﬂammation in non-allergic asthmatics.14 Aim of this study
was to evaluate the possible relation between skin reactivity
to autologous serum and clinical and laboratory character-
istics in a series of patients with non-allergic asthma.Subjects and methods
Fifty-ﬁve patients (19 men and 36 women, mean age7S.D.
51.7716 years), with non-allergic asthma were selected for
the study at the Respiratory Disease Outpatient Clinic of the
Fatebenefratelli Hospital of Milan. All patients underwent in
vivo autologous serum skin test (ASST), using saline solution
as negative control. Skin prick test with histamine 10mg/ml
was used as positive control. In 51 patients, in vitro basophilhistamine release assay was performed using basophils from
a normal donor. Non-allergic asthma was diagnosed on the
basis of clinical story, respiratory function tests, and
negativity of skin prick tests and/or speciﬁc IgE determina-
tions (UniCAP RAST, Phadia, Uppsala, Sweden). Serum total
IgE concentration was measured in all patients by UniCAP
system (Phadia, Uppsala, Sweden). All asthmatic subjects
had a 20% decrease of forced expiratory volume in 1 s
following inhalation of o8mmol methacholine or bronchial
obstruction at basal spirometry with reversibility after
inhalation of 200 mg albuterol. A detailed family and
personal history was collected for each patient. Asthma
was classiﬁed as intermittent, mild persistent, moderate
persistent or severe persistent according to Global Initiative
for Asthma (GINA) workshop report.19 Coexistence of non-
allergic rhinitis was diagnosed when non-allergic asthmatics
complained of symptoms such as nasal congestion, rhinor-
rhoea, itching/sneezing and impairment of smell, and two
or more of these symptoms were present for more than 1 h
on most days.20 If the patient reported gastroesophageal
symptoms, upper digestive tract endoscopy was performed.
The study protocol included two visits for each patient.
On the ﬁrst visit clinical history was collected and physical
examination, spirometry, methacholine provocation test
and skin prick or RAST tests were performed. If the patients
were considered eligible for the study, they underwent a
second visit during which venous blood was drawn and ASST
was performed. Furthermore, aliquots of blood were used
for basophil histamine release assay. One week before the
study systemic therapies, including anti-leukotrienes and
corticosteroids, were suspended. Patients with respiratory
infections at the time of the investigation were not
recruited. None of the patients was taking antihistamines
at the time of the investigation.
Twenty subjects with respiratory allergy (10 with rhinitis
and 10 with asthma) and 10 normal subjects were chosen as
control. These subjects (18 women, 12 men, mean
age7S.D. 38.978.3 years) were recruited among medical
doctors, students, nurses and patients of the Allergy and
Respiratory Disease Clinic. None of them was smoker.
The hospital ethical committee approved the study
protocol. Patients were informed about the aims of the
study and gave their informed consent.
Skin tests
The patients underwent intradermal test with 0.05ml of
sterile, fresh autologous serum and with saline (0.9%, w/v,
NaCl) as negative control. A skin prick test with histamine
10mg/ml was used as positive control. Readings were taken
at 30min. Only an unequivocal WHEAL formation in response
to serum injection was considered as a positive test. Skin
tests were considered positive when the weal diameter was
at least 1.5mm larger than negative control and were
graded according to the following scale: 1.5–3mm larger
than negative control (+), 3–4mm (++), 44mm (+++).
Basophil histamine release assay
In vitro serum histamine-releasing activity was assessed
in 51 patients with non-allergic asthma as previously
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A.L. Comi et al.2528described.17 Sera were tested with leucocyte suspensions
from one normal donor whose basophils were previously
shown to release 30% of total histamine content on
challenge with an optimal dose of goat polyclonal anti-
human IgE (Sigma Chemicals, St. Louis, MO, USA; 10 mg/ml).
In addition, in order to detect the presence of functionally
active anti-FceRI autoantibodies, basophil histamine
release was evaluated after stripping of membrane-bound
IgE with 10mmol/l lactic acid (pH 3.9, incubation for
3.5min at room temperature), a procedure that allows
dissociation of FceRI-bound IgE without damaging basophil
functional activity.21 Histamine concentration in the cell
supernatant was measured by an automated ﬂuorometric
method.22 Results were expressed as net percent histamine
release over total histamine content. A 5% release cut-off
value was used.Determination of antinuclear antibodies
Antinuclear antibodies were assayed by an indirect immuno-
ﬂuorescence method using a commercially available kitTable 1 Demographic and clinical characteristics of the non-al
Patient
no.
Age Sex Family
history
Rhinitis Other disea
1 54 F No Yes Gastroesop
2 70 F Yes Yes None
3 23 M No Yes None
4 26 F Yes Yes None
5 45 M No Yes None
6 65 F No No Gastroesop
7 31 F No No None
8 72 F Yes No None
9 46 F No Yes Gastroesop
10 31 F No Yes None
11 69 F No Yes Gastroesop
12 55 F Yes Yes None
13 66 M No Yes None
14 41 F No Yes None
15 52 F No Yes None
16 67 F No Yes None
17 34 F Yes Yes Acetyl salic
intolerance
18 38 M No Yes None
19 70 F No Yes Gastroesop
20 48 F No Yes Gastroesop
21 66 F No Yes None
22 16 F No Yes None
23 49 F Yes Yes None
24 29 F No No Autoimmun
25 75 F No No Chronic urt
autoimmun
gastroesoph
26 53 F No Yes Bronchiecta
27 32 F Yes Yes Chronic urt
28 34 F No Yes Gastroesop
29 73 M No Yes Psoriasis(Euroimmun AG, Lu¨beck, Germany) and were considered
positive at a dilution X1/160.
Statistical analysis
Results are expressed as mean7S.D. Fisher’s exact test was
used for statistical analysis. A P-value lower than 0.05 was
considered signiﬁcant.
Results
The demographical and clinical characteristics of ASST-
positive and ASST-negative patients are reported in Tables 1
and 2. ASST was positive in 29/55 non-allergic asthmatics
(53%), whereas it was negative in all 30 control subjects
(Po0.001). Intradermal injection of saline did not induce
the formation of a wheal with a diameter above 3mm
neither in patients nor in controls. A predominance of
female patients was found (36/55, 65%): 24 of them (67%)
were ASST-positive and 8 (33%) were ASST-negative
(Po0.001). Mean age of asthma onset was 44.4716.5 years,lergic ASST-positive asthmatic patients included in the study.
ses Age of asthma
onset
Severity of asthma
hageal reﬂux 53 Mild persistent
68 Mild persistent
22 Mild persistent
25 Mild persistent
43 Mild persistent
hageal reﬂux 63 Severe persistent
31 Mild persistent
62 Moderate persistent
hageal reﬂux 43 Severe persistent
21 Moderate persistent
hageal reﬂux 46 Severe persistent
30 Moderate persistent
50 Severe persistent
35 Moderate persistent
47 Mild persistent
63 Mild persistent
ylic acid 10 Moderate persistent
33 Mild persistent
hageal reﬂux 62 Moderate persistent
hageal reﬂux 40 Moderate persistent
65 Severe persistent
15 Mild persistent
40 Mild persistent
e thyroiditis 28 Mild persistent
icaria,
e thyroiditis,
ageal reﬂux
74 Mild persistent
sis 43 Moderate persistent
icaria 27 Moderate persistent
hageal reﬂux 27 Mild persistent
66 Moderate persistent
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Table 2 Demographic and clinical characteristics of the non-allergic ASST-negative asthmatic patients included in the study.
Patient
no.
Age Sex Family
history
Rhinitis Other diseases Age of asthma
onset
Severity of asthma
30 65 M Yes Yes Gastroesophageal reﬂux 62 Mild persistent
31 44 F No Yes Gastroesophageal reﬂux 37 Moderate persistent
32 45 F Yes No None 39 Mild persistent
33 49 M Yes No None 27 Severe persistent
34 65 M Yes No None 58 Moderate persistent
35 39 F Yes Yes None 29 Moderate persistent
36 33 M No Yes None 28 Moderate persistent
37 39 M No Yes None 32 Moderate persistent
38 38 M No Yes None 33 Moderate persistent
39 74 M No Yes None 68 Mild persistent
40 80 M No Yes None 60 Mild persistent
41 48 M No Yes None 41 Moderate persistent
42 33 M Yes Yes None 31 Mild persistent
43 66 F No Yes None 62 Moderate persistent
44 53 F Yes Yes Chronic urticaria 44 Moderate persistent
45 69 M Yes Yes None 63 Severe persistent
46 47 F No Yes None 42 Moderate persistent
47 67 F No Yes None 37 Moderate persistent
48 54 F Yes Yes Gastroesophageal reﬂux 53 Severe persistent
49 61 F No No Hypertension,
gastroesophageal reﬂux
57 Mild persistent
50 67 M No Yes None 63 Mild persistent
51 50 F Yes Yes None 40 Moderate persistent
52 66 F Yes No Autoimmune thyroiditis,
pernicious anemia,
gastroesophageal reﬂux
65 Moderate persistent
53 46 F No Yes None 41 Moderate persistent
54 40 M No Yes None 20 Mild persistent
55 77 M No Yes None 76 Mild persistent
Novel aspects in non-allergic asthma 2529without any signiﬁcant difference between ASST-positive
and ASST-negative patients (42.48717.57 and 46.46715.36
years, respectively). Family history was positive in 18 out
of 55 patients (33%) and, among these, 7 were ASST-positive
and 11 ASST-negative. Rhinitis was present in 45 out of
55 patients (82%); 24 patients of these were ASST-positive
and 21 ASST-negative. Only one patient reported ASA
intolerance and he was ASST-positive. Gastroesophageal
reﬂux (GER) was reported by 13 patients out of 55 (24%);
among these, 8 were ASST-positive and 5 ASST-negative.
Four patients (3 ASST-positive and 1 ASST-negative) were
active smokers and 10 (5 ASST-positive and 5 ASST-negative)
were past smokers. In all patients, either smokers or past
smokers, bronchial obstruction was reversible and chest
X-ray was normal. Laboratory ﬁndings in ASST-positive and
ASST-negative non-allergic asthmatic patients are reported
in Tables 3 and 4. Serum samples from six ASST-positive
patients and two ASST-negative patients induced in vitro
histamine release from normal donor’s basophils (16%). Sera
from 1 ASST-positive and 1 ASST-negative patient induced
histamine release from membrane IgE-stripped basophils.
Sera from 32 patients were assayed for ANA and 15 samples
were positive, i.e. showed the presence of ANA at a titerX1/160 (47%). A higher proportion of ANA positivity was
found among ASST-positive patients (12/22, 55%) than
among ASST-negative patients (3/10, 30%,), although the
difference did not reach statistical signiﬁcance. ANA
patterns in ASST-positive patients were the following: six
speckled, four homogeneous, one granular, one cytoplas-
matic, one few nuclear dots. ANA patterns in ASST-negative
patients were: one homogeneous, two granular.
Mean eosinophil percentage was 5.777% in ASST-positive
patients and 9.4711% in ASST-negative patients (p n.s.).
Total IgE levels were 180.67391 kU/l (mean7S.DU) in ASST-
positive and 87.57146 kU/l in ASST-negative patients, but
the difference was not statistically signiﬁcant. Asthma
severity was not different in ASST-positive and ASST-
negative patients. Two ASST-positive and one ASST-negative
patient suffered from chronic urticaria. Two ASST-positive
patients and one ASST-negative patient were affected with
autoimmune thyroiditis (5.4%). In one patient of these, who
was ASST-positive, chronic urticaria and autoimmune thyr-
oiditis coexisted. The ASST-negative asthmatic patient who
suffered from autoimmune thyroiditis also had pernicious
anemia. Finally, one ASST-positive patient was also affected
with psoriasis.
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Table 3 Laboratory characteristics of the ASST-positive non-allergic asthmatic patients included in the study.
Patient no. Age Sex Total IgE
(kU/l)
Basophil histamine
release (%)
Blood
eosinophils (%)
Autoantibodies
1 54 F 110 1.8 10.5 –
2 70 F 25.6 0.5 3.4 ANA 1:160 ASMA 1:320
3 23 M 68.8 5.9 4.8 Neg
4 26 F 31 2.7 0.9 Neg
5 45 M 125 7.7 6.9 ANA 1:160
6 65 F 6.54 24.1 1.6 Neg
7 31 F 145 3.1 7.4 ANA 1:80
8 72 F 24.4 1.8 4.8 ANA 1:160
9 46 F 10 0.5 0.7 Neg
10 31 F 32.5 1.4 0.9 Neg
11 69 F 912 3 6 ANA 1:320
12 55 F 15.4 2.2 – –
13 66 M 76 1.8 7 Neg
14 41 F 162 1.7 9.5 –
15 52 F 134 1.7 31.6 –
16 67 F 28.4 2.1/22.6y –
17 34 F 31.1 2.1 3.6 ANA 1:160
18 38 M 87.7 2.8 – –
19 70 F 912 2.1/36.9y – –
20 48 F 15.4 0.5 2.1 Neg
21 66 F 1843 0.5 15.2 ANA 1:160
22 16 F 17.2 10.9 1.5 ANA 1:160
23 49 F 67 0.5 9.3 Neg
24 29 F 186 2.3 1.9 ANA 1:160
25 75 F 10.8 1.8 2 Neg
26 53 F 47.4 1.8 2.1 ANA 1:160
27 32 F 49.9 3.6 1.4 ANA 1 :160
28 34 F 48.6 1.8 4 ANA 1:640 AMA 1:640
29 73 M 15 – 2.5 ANA 1:320
ANA: antinuclear antibodies; ASMA: antismooth muscle antibodies.
Positive results of basophil histamine release are indicated in bold.
Basophil histamine release: the test was considered positive when net histamine release was above 5% of total histamine content.
yBasophil histamine release after lactic acid stripping of IgE membrane.
A.L. Comi et al.2530Discussion
The clinical characteristics of our patients were typical of
non-allergic asthma. The mean age was 51.7 years and the
mean age of asthma onset was 44.4 years, conﬁrming that
non-allergic asthma has a later onset in life than allergic
asthma.1 Furthermore, a clear female preponderance was
found (65%) in agreement with other clinical studies on
asthmatic patients.1 Coexistence of rhinitis was reported by
most patients (82%), in keeping with the one airway disease
concept which considers asthma and rhinitis as the expres-
sion of a systemic inﬂammatory disease interesting at the
same time upper and lower airways.23 ASST was positive in
29/55 (53%) patients and negative in all control subjects. We
found an in vitro histamine-releasing activity from normal
donor’s basophils in eight non-allergic asthmatic patients.
This activity could be caused by autoantibodies speciﬁc for
the high-afﬁnity IgE receptor (FceRI) or for IgE, as it has
been demonstrated in patients with chronic urticaria or by
other undeﬁned histamine-releasing factors.16–18, 24–26In vitro basophil histamine release assay could be
considered as a functional test for histamine-releasing
factors, in particular for histamine-releasing autoantibodies
directed against the high-afﬁnity IgE receptor or against
IgE.18 Positivity of basophil histamine release assay in 8/51
(16%) patients indicates that circulating histamine-releasing
factors can be detected in a subgroup of non-allergic
asthmatics.
The observation of ASST and basophil histamine release
positivity in some non-allergic asthmatics may shed some
light on the mechanism of the disease, suggesting an
autoreactive/autoimmune basis for this disorder. Female
preponderance and frequent occurrence of ANA positivity
also suggest that an autoimmune mechanism may underlie
non-allergic asthma.27–30 In fact, it is well documented that
autoimmune disorders have a higher prevalence in female
population, and in turn ANA positivity suggests a propensity
towards autoimmune phenomena. Prevalence of ANA posi-
tivity in non-allergic asthmatic patients (55% among ASST-
positive patients and 30% among ASST-negative patients)
ARTICLE IN PRESS
Table 4 Laboratory characteristics of the ASST-negative non-allergic asthmatic patients included in the study.
Patient no. Age Sex Total IgE
(kU/l)
Basophil histamine
release (%)
Blood
eosinophils (%)
Autoantibodies
30 65 M 5.7 2.3 2.4 ANA 1:80
31 44 F 9.04 1.8 2.2 ANA 1:40
32 45 F 14.9 2.4 – –
33 49 M 479 2.1 – –
34 65 M 5.39 2.4 – –
35 39 F 29.1 3.5 – –
36 33 M 19.1 2 – –
37 39 M 5.6 2.1 – –
38 38 M 49.5 1.8 – –
39 74 M 54.8 3.2 – –
40 80 M 40.2 3.7 – –
41 48 M 46.9 1.6 – –
42 33 M – – – –
43 66 F – – 35.3 –
44 53 F 101 2.3 – –
45 69 M 560 – 5.5 Neg
46 47 F 14 1.8 Neg
47 67 F 58.5 2.7 4.7 ANA 1:160
48 54 F 11 0.9 11.5 Neg
49 61 F 29 5.5 1.8 Neg
50 67 M 169 4.5/9.2y 29 Neg
51 50 F 4.25 1.8 1.9 –
52 66 F 193 3.1 3.9 ANA 1:160
53 46 F 2.7 – –
54 40 M 20.7 1.4 6.5 Neg
55 77 M 92.7 – 7.5 ANA 1:180
ANA: antinuclear antibodies.
Positive results of basophil histamine release are indicated in bold.
Basophil histamine release: the test was considered positive when net histamine release was above 5% of total histamine content.
yBasophil histamine release after lactic acid stripping of IgE membrane.
Novel aspects in non-allergic asthma 2531was higher than that reported in the general healthy
population (6–15%),31,32 suggesting an immune system
dysregulation, namely a reduced efﬁciency of regulatory T
cells which should avoid immune responses against auto-
antigens. It is also interesting to note that three patients
suffered from chronic urticaria, a disease that often has an
autoimmune origin and which has a low prevalence in the
general population (0.1%).33 Recently, Asero et al. have
demonstrated that bronchial hyperresponsiveness is a
common feature in patients with chronic urticaria conﬁrm-
ing the hypothesis of a link between the two diseases.34
Three patients were affected by autoimmune thyroiditis and
in one patient, who was ASST-positive, chronic urticaria and
autoimmune thyroiditis coexisted. One other patient suf-
fered from autoimmune thyroiditis and pernicious anemia.
Percentage of positivity of anti-thyroid peroxidase auto-
antibodies among non-allergic asthmatic patients is in line
with that observed in the general population (4% in males
and 10% in women).35 However, the overall increased
prevalence of ANA positivity and chronic urticaria in non-
allergic asthmatics conﬁrms the immune dysfunction and
the propensity to autoimmune phenomena.
In spite of the possible contribution to the elucidation of
the disease mechanism, ASST positivity was not associatedwith any deﬁnite clinical characteristic. Severity of asthma
was similar in ASST-positive and ASST-negative patients.
Furthermore, no differences were found between ASST-
positive and ASST-negative asthmatics regarding other
clinical and laboratory characteristics. ‘‘Mean age’’ and
‘‘mean age of asthma onset’’ were similar, and no signiﬁcant
differences were found regarding prevalence of rhinitis
symptoms, severity of asthma symptoms, peripheral blood
eosinophilia, ASA hypersensitivity and family history. In-
creased total IgE levels were found in our patients in
comparison with general population, with a trend towards
higher levels in ASST-positive patients. This probably reﬂects
a strong immune system activation with increased produc-
tion of cytokines enhancing IgE synthesis, such as IL-4 and
IL-13.7–9,12,36
In conclusion, our ﬁndings indicate that ASST is fre-
quently positive in patients with non-allergic asthma
and that a proportion of patients, which is not negligible,
has functional evidence of circulating histamine-releasing
factors, suggesting an autoreactive/autoimmune basis
for the disease. Female preponderance and frequent
occurrence of ANA positivity also support the hypothesis
of an autoreactive/autoimmune basis in non-allergic
asthma.
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